Please sign in to follow a disease.
Verastem, Inc.
Clinical trials sponsored by Verastem, Inc., explained in plain language.
A biopharmaceutical company developing drugs to treat cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets Hard-to-Treat lung cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- New pill targets stubborn colorectal cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- New pill targets tough pancreatic cancer mutation Results expected Jun 2027 (estimated) May already have reported ↗
- Can a Two-Drug combo keep fighting a rare ovarian cancer? Results expected Aug 2027 (estimated)
-
New drug combo targets hard-to-treat lung cancer mutation
Disease control OngoingThis study tests whether combining two or three drugs can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C). The drugs aim to block cancer growth signals. About 153 adults who have or haven't received prior KRAS-targeting therapy will take part…
Phase 1/2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug cocktail targets tough ovarian cancer in japanese women
Disease control OngoingThis phase 2 study tests a combination of two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has returned after platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and how safe it is. The trial is activ…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New cocktail of targeted drugs and chemo takes on pancreatic cancer
Disease control OngoingThis study tests whether adding two targeted drugs (avutometinib and defactinib) to standard chemotherapy can help people with metastatic pancreatic cancer that hasn't been treated yet. About 40 adults with this cancer will receive the combination. The goal is to find the safest …
Phase 1/2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:18 UTC